PT3006038T - Doses únicas de oritavancina para tratamento ou prevenção de uma infeção bacteriana - Google Patents

Doses únicas de oritavancina para tratamento ou prevenção de uma infeção bacteriana

Info

Publication number
PT3006038T
PT3006038T PT151957263T PT15195726T PT3006038T PT 3006038 T PT3006038 T PT 3006038T PT 151957263 T PT151957263 T PT 151957263T PT 15195726 T PT15195726 T PT 15195726T PT 3006038 T PT3006038 T PT 3006038T
Authority
PT
Portugal
Prior art keywords
oritavancin
treatment
methods
single doses
doses
Prior art date
Application number
PT151957263T
Other languages
English (en)
Portuguese (pt)
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3006038(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Medicines Co filed Critical The Medicines Co
Publication of PT3006038T publication Critical patent/PT3006038T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT151957263T 2008-08-30 2009-08-29 Doses únicas de oritavancina para tratamento ou prevenção de uma infeção bacteriana PT3006038T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9331408P 2008-08-30 2008-08-30
US9349708P 2008-09-02 2008-09-02

Publications (1)

Publication Number Publication Date
PT3006038T true PT3006038T (pt) 2024-08-23

Family

ID=41722337

Family Applications (1)

Application Number Title Priority Date Filing Date
PT151957263T PT3006038T (pt) 2008-08-30 2009-08-29 Doses únicas de oritavancina para tratamento ou prevenção de uma infeção bacteriana

Country Status (18)

Country Link
US (2) US8420592B2 (enExample)
EP (3) EP2337575B1 (enExample)
JP (1) JP5782615B2 (enExample)
CN (2) CN102215858A (enExample)
AU (1) AU2009285564B2 (enExample)
CA (1) CA2736860C (enExample)
DK (2) DK2337575T3 (enExample)
EA (1) EA020490B1 (enExample)
ES (2) ES2994966T3 (enExample)
FI (1) FI3006038T3 (enExample)
HU (3) HUE027373T2 (enExample)
MX (1) MX2011002249A (enExample)
NL (1) NL300834I2 (enExample)
NO (1) NO2016019I2 (enExample)
NZ (1) NZ591525A (enExample)
PL (2) PL3006038T3 (enExample)
PT (1) PT3006038T (enExample)
WO (1) WO2010025438A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5782615B2 (ja) * 2008-08-30 2015-09-24 ザ メディシンズ カンパニー オリタバンシンの単回用量を用いる治療の方法
PT2424559T (pt) 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
WO2014031681A1 (en) * 2012-08-20 2014-02-27 The University Of Chicago Inhibiting gram positive bacteria
WO2014176068A2 (en) * 2013-04-22 2014-10-30 The Medicines Company Treatment and prevention of bacterial skin infections using oritavancin
LT3038616T (lt) 2013-08-26 2023-05-25 Melinta Therapeutics, Inc. Bakteriemijos ir osteomielito gydymo būdai naudojant oritavanciną
EP3038615A4 (en) * 2013-08-28 2017-04-12 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins
US20170119793A1 (en) * 2014-06-12 2017-05-04 Cem-102 Pharmaceuticals, Inc. Compositions and methods for treating bone and joint infections
MX385925B (es) * 2014-07-17 2025-03-18 The Medicines Co Oritavancina de alta pureza y método para producir la misma.
CA3014294A1 (en) 2016-02-18 2017-08-24 Melinta Therapeutics, Inc. Oritavancin formulations
WO2017179003A1 (en) * 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
CN108409837B (zh) * 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
US5994297A (en) * 1997-08-22 1999-11-30 Eli Lilly And Company Therapy for Staphylococcus aureus
SK285970B6 (sk) * 1999-05-03 2007-12-06 Eli Lilly And Company Použitie N DISACC-(4-(4-chlórfenyl)benzyl)A82846Balebo teikoplanínu na prípravu liečiva na dlhodobú prevenciu infekcií Streptococcus pneumoniae a farmaceutické kompozície s ich obsahom
DE60136926D1 (de) 2000-05-02 2009-01-22 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
WO2003102171A1 (en) * 2002-05-28 2003-12-11 Becton, Dickinson And Company Expansion and transdifferentiation of human acinar cells
WO2004017925A2 (en) 2002-08-23 2004-03-04 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20040127403A1 (en) * 2002-09-06 2004-07-01 Francesco Parenti Methods for treating and preventing Gram-positive bacteremias
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
CA2664444C (en) * 2006-09-25 2015-10-27 Melinta Therapeutics, Inc. Use of oritavancin for prevention and treatment of anthrax
JP5782615B2 (ja) 2008-08-30 2015-09-24 ザ メディシンズ カンパニー オリタバンシンの単回用量を用いる治療の方法
PT2424559T (pt) * 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
EP3038615A4 (en) * 2013-08-28 2017-04-12 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins

Also Published As

Publication number Publication date
JP2012501349A (ja) 2012-01-19
EP2337575A4 (en) 2012-10-17
DK3006038T3 (da) 2024-08-26
JP5782615B2 (ja) 2015-09-24
WO2010025438A9 (en) 2010-05-14
AU2009285564B2 (en) 2014-05-22
EP3006038B1 (en) 2024-07-03
NO2016019I2 (no) 2019-01-25
EA201100413A1 (ru) 2012-01-30
EP2337575A1 (en) 2011-06-29
HUE068423T2 (hu) 2024-12-28
EP3006038A1 (en) 2016-04-13
ES2994966T3 (en) 2025-02-04
CN106620649A (zh) 2017-05-10
EA020490B1 (ru) 2014-11-28
PL3006038T3 (pl) 2024-11-12
FI3006038T3 (fi) 2024-08-12
DK2337575T3 (en) 2016-05-23
US20110201546A1 (en) 2011-08-18
CA2736860A1 (en) 2010-03-04
US20130172237A1 (en) 2013-07-04
US12514899B2 (en) 2026-01-06
WO2010025438A2 (en) 2010-03-04
EP2337575B1 (en) 2016-04-13
EP4464375A2 (en) 2024-11-20
NO2016019I1 (no) 2016-10-11
NL300834I2 (enExample) 2016-11-16
NZ591525A (en) 2014-03-28
HUS1600039I1 (hu) 2016-11-28
ES2570401T3 (es) 2016-05-18
CN102215858A (zh) 2011-10-12
US8420592B2 (en) 2013-04-16
MX2011002249A (es) 2011-06-24
EP4464375A3 (en) 2025-02-26
AU2009285564A1 (en) 2010-03-04
PL2337575T3 (pl) 2016-09-30
CA2736860C (en) 2020-04-28
HUE027373T2 (hu) 2016-09-28

Similar Documents

Publication Publication Date Title
NO2016023I1 (no) Glycerol fenylbutyrat
PL2337575T3 (pl) Sposoby leczenia z użyciem pojedynczych dawek orytawancyny
ZA201006648B (en) Methods of treatment
IL215131A0 (en) Methods of treatment using combination therapy
PL2245037T3 (pl) Nowe związki i sposoby leczenia
IL217777A0 (en) Methods for treatment of pain
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
ZA201109517B (en) Treatment method
PL2957292T3 (pl) Terapia w przypadku bielactwa nabytego
ZA201000225B (en) Treatment of depression
PL2424529T3 (pl) Nowe postępowania terapeutyczne z zastosowaniem centakwiny
EP2164494A4 (en) Methods of Treatment
GB0723100D0 (en) Treatment of HFnEF
ZA201100163B (en) Unit dosage of apadenoson
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
GB2460445B (en) Treatment of ringworm
EP2203432A4 (en) PROCESSING METHOD
SI2330892T1 (sl) Postopki zdravljenja z uporabo zdravil, ki odstranjujejo amoniak
GB0700969D0 (en) Methods of treatment
AU2008902372A0 (en) Methods of treatment
GB2465211B (en) Treatment Solution
GB0816217D0 (en) Treatment of hepatitis C
GB0823435D0 (en) Method of treatment
AU2009904460A0 (en) Methods of treatment
AU2009902633A0 (en) Methods of treatment